How finally accepting her diagnosis and being proactive with her health helped one woman manage her lung condition.

An Insmed drug developed for a serious chronic lung disorder with no FDA-approved therapies handily beat a placebo in a pivotal clinical trial, preliminary results that set the stage for a regulatory ...

Insmed's freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first ...

Bronchiectasis is a chronic respiratory disorder characterised by irreversible dilation of the bronchi, leading to impaired mucociliary clearance, recurrent infections and progressive respiratory ...

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. Pamela J. McShane, MD, explores the clinical ...

Bronchiectasis, a condition defined by widened lung airways, cough and sputum production, and frequent infections, often presents along with chronic obstructive pulmonary disease (COPD). This overlap ...

Suspected bronchiectasis, defined as a combination of clinical symptoms and radiologic evidence of abnormal airways, is associated with a 15% higher risk for death in adults with normal spirometry, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Bronchiectasis ...

Dr Metersky provides an overview of current treatment strategies for managing patients diagnosed with bronchiectasis. The main bronchiectasis management goals are improving quality of life, decreasing ...

(RTTNews) - Insmed Inc. (INSM), on Thursday, announced that its New Drug Application for Brensocatib, an investigational treatment for patients with non-cystic fibrosis bronchiectasis, has been ...